This self-check reflects FDA-approved eligibility and the boxed-warning contraindications for GLP-1 weight-loss medications (semaglutide / Wegovy and tirzepatide / Zepbound). It never diagnoses or prescribes — only a licensed medical provider can.

• Eligibility (BMI ≥30, or ≥27 with a weight-related condition), boxed warning & contraindications — FDA label: Wegovy · FDA label: Zepbound
• Average trial weight loss (semaglutide ~15%, tirzepatide ~20%) — NEJM STEP-1 · SURMOUNT-1
• Prescription-only, medical supervision — Mayo Clinic